GlassScriptPhysician profile
Joselline Johnson
NPI 1982260550
$1,403.94
in general payments reported to CMS, 2019-2025
11 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $175 · 2023: $17.18 · 2024: $669 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $663.56 | 2021-2024 | Fasenra, Breztri, Tagrisso |
| Dendreon Pharmaceuticals LLC | $131.59 | 2025 | Provenge |
| Amgen INC. | $128.35 | 2024 | Krystexxa |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Nucala |
| Ethicon INC. | $121.32 | 2021 | |
| Coloplast Corp | $82.93 | 2024 | |
| Abbvie INC. | $75.00 | 2024 | |
| Atricure, INC. | $23.45 | 2021 | |
| Novo Nordisk INC | $20.04 | 2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $17.35 | 2024 | Quviviq |
| Medtronic, INC. | $15.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joselline Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.